Dotinurad

Dotinurad
Clinical data
Trade names	Urece
Other names	FYU-981
ATC code	None;
Legal status
Legal status	Rx-only (Japan);
Identifiers
	IUPAC name (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone;
CAS Number	1285572-51-1 ;
PubChem CID	51349053 ;
DrugBank	DB16145 ;
ChemSpider	59718651 ;
UNII	305EB53128 ;
KEGG	D11071 ;
ChEMBL	ChEMBL4594446 ;
Chemical and physical data
Formula	C14H9Cl2NO4S
Molar mass	358.19 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl;
	InChI InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2; Key:VOFLAIHEELWYGO-UHFFFAOYSA-N;

Last updated November 12, 2025

Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia.^[1]^[2] It was developed by Fuji Yakuhin and approved for use in Japan in 2020.^[2]^[3] The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.^[3]^[4]

Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity by inhibiting URAT1/SLC22A12 receptor. It and epaminurad are structural analogs of Benzbromarone. ^[5]^[6]

References

↑ Kuriyama S (March 2020). "Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia". Clinical and Experimental Nephrology. 24 (Suppl 1): 1–5. doi:10.1007/s10157-019-01811-9. PMC 7066308 . PMID 31754883.
1 2 "List of Approved Products" (PDF). Pharmaceuticals and Medical Devices Agency.
1 2 "Fortress takes on dotinurad in USA and Europe". 5 November 2020. Retrieved 23 June 2021.
↑ "Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe". 10 May 2021. Retrieved 23 June 2021.
↑ Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. (October 2019). "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor". The Journal of Pharmacology and Experimental Therapeutics. 371 (1): 162–170. doi: 10.1124/jpet.119.259341 . PMID 31371478. S2CID 199382932.{{cite journal}}: CS1 maint: overridden setting (link)
↑ Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T (October 2020). "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity". ACS Medicinal Chemistry Letters. 11 (10): 2017–2023. doi:10.1021/acsmedchemlett.0c00176. PMC 7549256 . PMID 33062187.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Kuriyama S (March 2020). "Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia". Clinical and Experimental Nephrology. 24 (Suppl 1): 1–5. doi:10.1007/s10157-019-01811-9. PMC 7066308 . PMID 31754883.

[pmda-2] 1 2 "List of Approved Products" (PDF). Pharmaceuticals and Medical Devices Agency.

[thepharmaletter-3] 1 2 "Fortress takes on dotinurad in USA and Europe". 5 November 2020. Retrieved 23 June 2021.

[4] "Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe". 10 May 2021. Retrieved 23 June 2021.

[5] Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. (October 2019). "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor". The Journal of Pharmacology and Experimental Therapeutics. 371 (1): 162–170. doi: 10.1124/jpet.119.259341 . PMID 31371478. S2CID 199382932.{{cite journal}}: CS1 maint: overridden setting (link)

[6] Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T (October 2020). "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity". ACS Medicinal Chemistry Letters. 11 (10): 2017–2023. doi:10.1021/acsmedchemlett.0c00176. PMC 7549256 . PMID 33062187.

[1]

[2]

[3]

[4]

[5]

[6]